Gender transition
Adjunct considerations during gender-affirming care — surgical recovery, skin/hair effects of HRT, sexual function. Peptides are adjuncts, never alternatives to gender-affirming medical care.
What changes during this transition
Gender-affirming care (HRT — testosterone or estradiol/anti-androgens — and where pursued, surgery) is the standard of care delivered by gender-affirming clinicians. The editorial frame for this axis is **adjunct, not alternative** — peptides cannot replace HRT for transition; they can support adjacent goals (post-surgical recovery, skin/hair adaptation, sexual function after anatomical or hormonal changes). Tissue-repair peptides (BPC-157, TB-500) have community-experiential use for post-vaginoplasty / post-phalloplasty / post-top-surgery recovery — animal-data foundation, no transition-specific human trials. GHK-Cu addresses skin and hair adaptation during HRT shifts (well-established cosmetic-dermatology applications carry over). PT-141 addresses CNS-arousal issues that may persist despite well-optimized HRT (T or E2 independent). Thymosin alpha-1 has approved-market use abroad for immune support — relevant where surgery + HRT shifts converge with stress and infection risk.
Important caveat
Coordinate with your gender-affirming care team — primary care + HRT prescriber + surgeon (if relevant) — before adding any peptide. The team is tracking labs, surgical-recovery timelines, and HRT effects holistically; peptide additions need to fit into that picture. Some peptides have direct contraindications worth flagging: PT-141 raises BP transiently (CV history matters); melanotan-2 stimulates melanocytes (mole-watchers and personal/family melanoma history are flags). Mental health support during transition outranks any peptide — dysphoria + body image + libido are tangled, and peptides address narrow slices, not the whole picture.
Peptides editorially relevant to gender transition
5 peptides from the library — each evidence-tiered honestly.
- BPC-157Tier 3
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.
- TB-500Tier 3
Thymosin Beta-4 fragment
Animal-data peptide marketed as a tissue-repair adjunct. No published human RCTs for musculoskeletal indications.
- GHK-CuTier 2
Copper tripeptide
Strong topical evidence in skin and wound healing. Injectable systemic claims are an entirely different evidence base and tier.
- PT-141 (Bremelanotide)Tier 1
Melanocortin receptor agonist
FDA-approved as Vyleesi for premenopausal HSDD. Off-label use for male erectile function and on-demand libido is widespread but supported by far thinner evidence.
- Thymosin Alpha-1Tier 2
Immunomodulatory peptide
Approved in 30+ countries for chronic hepatitis B and C and as a sepsis adjunct in critically ill patients — but not in the US. Evidence quality varies sharply by indication, and the popular 'general immune support' framing has no clinical backing.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.